HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 2, 2026 is -56.93. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -66.74 — a change of -14.70% (higher).

EV/FCF

-56.93

YoY

-14.70%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of HaTay Pharmaceutical JSC is 2024 -56.93 . EV/FCF (Enterprise Value to Free Cash Flow) of HaTay Pharmaceutical JSC was 2023 -66.74 . It decreases by -14.70% higher compared to the previous year.

The HaTay Pharmaceutical JSC EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-410.43 VND
Jan 1, 2018
90.29 VND
Jan 1, 2019
95.35 VND
Jan 1, 2020
1,129.39 VND
Jan 1, 2021
-73.34 VND
Jan 1, 2022
-22.58 VND
Jan 1, 2023
-66.74 VND
Jan 1, 2024
-56.93 VND
The HaTay Pharmaceutical JSC EV/FCF history
YEAREV/FCFYoY
-56.93-14.70%
-66.74+195.62%
-22.58-69.21%
-73.34-106.49%
1,129.39+1,084.52%
95.35+5.60%
90.29-122.00%
-410.43-324.48%
182.84-177.81%
-235.00-83.87%
-1,456.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

EV/FCF (Enterprise Value to Free Cash Flow) of HaTay Pharmaceutical JSC is -56.93 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of HaTay Pharmaceutical JSC changed from -66.74 to -56.93, representing a -14.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s HaTay Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC